Form 4: CFO Sells IBO Shares Under Pre-Arranged Plan

IMPACT BIOMEDICAL CFO Todd Macko sold 45,000 shares of common stock in late March 2026 under a Rule 10b5-1 trading plan.

Summary

• Todd D. Macko, Chief Financial Officer of IMPACT BIOMEDICAL INC. (IBO), reported two sales of common stock.
• On March 25, 2026, Mr. Macko sold 1,600 shares of common stock at a price of $0.6008 per share.
• Following this transaction, Mr. Macko beneficially owned 198,122 shares directly.
• On March 27, 2026, an additional 43,400 shares of common stock were sold at a price of $0.5615 per share.
• After both reported transactions, Mr. Macko's direct beneficial ownership stands at 155,122 shares.
• Both transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine disclosure of insider selling, with the 10b5-1 plan mitigating immediate negative sentiment, suggesting a pre-planned financial move rather than a reaction to new information.

Positives

• The transactions were conducted under a Rule 10b5-1(c) plan, indicating they were pre-arranged and not based on immediate, non-public information, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• The Chief Financial Officer reduced his direct beneficial ownership in the company by a total of 45,000 shares, which could be interpreted by some investors as a reduction in insider confidence.

Industry Context

StockSavvy.ai notes that insider sales, even when conducted under a Rule 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's view of future company prospects. While a 10b5-1 plan mitigates the immediate negative interpretation, a reduction in insider ownership is always a data point for market participants.

Corporate Governance

Stakeholder Impact

• Shareholders might view the reduction in the CFO's direct equity stake with caution, although the disclosure of a 10b5-1 plan provides context that these sales were pre-planned and not necessarily indicative of a change in company outlook.

Key Dates

Recommendation

The sale by the CFO, while notable, was conducted under a pre-arranged 10b5-1 trading plan, which suggests a planned financial event rather than a reaction to new material information. Without additional context on the company's performance or other insider activity, a 'hold' recommendation is appropriate as this transaction alone does not provide a strong directional signal for the stock.

Keywords

IMPACT BIOMEDICAL, IBO, Todd Macko, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 plan